Pulmonary vascular disease & thromboembolism
Rosuvastatin use improves measures of coagulation in patients with venous thrombosis
Primary result · FVIII:C changeResult — go to the resultMean difference −6.7 IU/dL 95% CI −12.0 to −1.4Authors' conclusion
Rosuvastatin 20 mg/day substantially improved the coagulation profile among patients with prior VT.
Study context
- Population
- Patients with prior venous thrombosis (VT)randomized
- Participants
- 247 patients
- Comparison
- Rosuvastatin 20 mg/day for 4 weeks vs no intervention
- Primary endpoint
- factor (F) VIII:C
- Follow-up
- End of study (4 weeks)
Primary result
FVIII:C change · end of study
Mean difference
−6.7 IU/dL
95% CI −12.0 to −1.4
Rosuvastatinvs No intervention
mean difference −6.7 IU/dL (95% CI −12.0 to −1.4)
As reported in the abstract
Further findings
vWF:Ag, FVII:C, FXI:C, D-dimer · end of study
- Mean levels clearly decreased with rosuvastatin; hardly differed in non-users
Coagulation factors, by unprovoked VT and CV risk factors (subgroup)
- Decrease more pronounced with unprovoked VT and with CV risk factors
Original publication
Rosuvastatin use improves measures of coagulation in patients with venous thrombosis. Eur Heart J. Published 30 January 2018. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →